EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL‐Chile Study

Marcela Espinoza iD, Jorge Rojas-Vallejos iD, Nicolás Rodríguez iD, Gonzalo Guerrero, Miguel López, Natalia Aranguiz, Guillermo Conte iD, Francisco Samaniego, Nicolás Quinteros iD, Daniel Astete, Lucas Carcamo, Constanza Flores und 8 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Marcela Espinoza und 19 weiteren Autor:innen. Beteiligte Einrichtung: Clínica Dávila, Santiago, Chile. Hauptthemen laut MEDLINE: Inotuzumab Ozogamicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Agents, Immunological, Neoplasm Recurrence, Local. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inotuzumab Ozogamicin (InO) has shown efficacy in relapsed/refractory acute lymphoblastic leukemia (R/R ALL), but evidence from Latin America is scarce. We evaluated the outcomes of Chilean patients treated with InO in public and private health centers.

Methods

We retrospectively analyzed 35 patients with R/R ALL (median age 33 years; 54% male). Twenty percent had BCR::ABL‐positive ALL, 78% expressed CD22, and 91% expressed CD19. Response rates, measurable residual disease (MRD), survival outcomes, and treatment‐related toxicities were assessed. Multivariate analyses explored prognostic factors.

Results

Complete remission or remission with incomplete recovery (CR/CRi) was achieved in 74% of patients. Among those evaluated, 82% reached MRD < 0.01%. Patients undergoing allogeneic hematopoietic stem cell transplantation (Allo‐HSCT) after InO had superior overall survival (OS) compared with those who did not (24.2 vs. 5.2 months). Median progression‐free survival (PFS) was 6.9 months and median OS was 8.8 months. Sinusoidal obstruction syndrome occurred in 14% of patients but was generally mild. Multivariate analysis identified comorbidities and high blast counts as adverse prognostic factors, whereas MRD negativity and subsequent Allo‐HSCT were associated with improved outcomes.

Conclusions

InO demonstrated high remission and MRD negativity rates in Chilean patients with R/R ALL, with OS and PFS comparable to existing research. Although SOS incidence was higher, it was generally mild. Achieving MRD negativity and proceeding to Allo‐HSCT provided the greatest survival benefit. Study limitations include short follow‐up and limited data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inotuzumab OzogamicinPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Agents, ImmunologicalNeoplasm Recurrence, LocalHumansMaleFemaleAdultRetrospective StudiesMiddle AgedYoung AdultHematopoietic Stem Cell TransplantationChileAdolescentNeoplasm, ResidualRemission InductionPrognosis

Stichwörter der Autor:innen

Inotuzumab Ozogamicinacute lymphoblastic leukemiasinusoidal obstruction syndrome

Substanzen

Inotuzumab OzogamicinAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Clínica Dávila, Santiago, Chile.
  • Universidad Andres Bello, Santiago, Chile.
  • Hospital Barros Luco Trudeau, Santiago, Chile.
  • Clínica RedSalud Vitacura, Santiago, Chile.
  • Clínica Alemana, Santiago, Chile.
  • Hospital Clínico de la Universidad de Chile, Santiago, Chile.

ORCID-Profile: Marcela Espinoza, Jorge Rojas-Vallejos, Nicolás Rodríguez, Guillermo Conte, Nicolás Quinteros, Mauricio Chandía, Jorge Valenzuela, Marcelo Navarrete, Yorman Flores, Joaquín Jerez

Zitieren

APA

Espinoza, M., Rojas-Vallejos, J., Rodríguez, N., Guerrero, G., López, M., Aranguiz, N., Conte, G., Samaniego, F., Quinteros, N., Astete, D., Carcamo, L., Flores, C., Huerta, X., Chandía, M., Valenzuela, J., Navarrete, M., Flores, Y., Larrazabal, A., Zapata, E., & Jerez, J. (2025). Real‐World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL‐Chile Study. Cancer Medicine. https://doi.org/10.1002/cam4.71230

Vancouver

Espinoza M, Rojas-Vallejos J, Rodríguez N, Guerrero G, López M, Aranguiz N, et al. Real‐World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL‐Chile Study. Cancer Medicine. 2025. doi:10.1002/cam4.71230

BibTeX
@article{Espinoza2025,
  author = {Espinoza, Marcela and Rojas-Vallejos, Jorge and Rodríguez, Nicolás and Guerrero, Gonzalo and López, Miguel and Aranguiz, Natalia and Conte, Guillermo and Samaniego, Francisco and Quinteros, Nicolás and Astete, Daniel and Carcamo, Lucas and Flores, Constanza and Huerta, Ximena and Chandía, Mauricio and Valenzuela, Jorge and Navarrete, Marcelo and Flores, Yorman and Larrazabal, Agatha and Zapata, Edgar and Jerez, Joaquín},
  title = {Real‐World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL‐Chile Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71230}
}
Kostenlos starten →